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Background: EGFR and KRAS mutations are mutually exclusive 
and predict outcomes with epidermal growth factor receptor (EGFR) 
tyrosine kinase inhibitor (TKI) treatment in patients with stage IV 
lung cancers. The clinical significance of these mutations in patients 
with resected stage I–III lung cancers is unclear.
Methods: At our institution, resection specimens from patients 
with stage I–III lung adenocarcinomas are tested for the presence 
of EGFR or KRAS mutations during routine pathology analysis such 
that the results are available before consideration of adjuvant therapy. 
In a cohort of 1118 patients tested over 8 years, overall survival was 
analyzed using multivariate analysis to control for potential con-
founders, including age, sex, stage, and smoking history. The impact 
of adjuvant erlotinib or gefitinib was examined in an independent 
data set of patients exclusively with EGFR mutation, in which date 
of recurrence was recorded. 
Results: In the overall population, we identified 227 KRAS (25%) 
and 222 EGFR (20%) mutations. Patients with EGFR-mutant lung 
cancers had a lower risk of death compared with those without EGFR 
mutations, overall survival (OS) HR 0.51 (95% confidence interval 
[CI]: 0.34–0.76, p < 0.001). Patients with KRAS-mutant lung cancers 
had similar outcomes compared with individuals with KRAS wild-
type tumors, OS HR 1.17 (95% CI: 0.87–1.57, p = 0.30). A separate 
data set includes only patients with EGFR-mutant lung cancers iden-
tified over 10 years (n = 286). In patients with resected lung cancers 
and EGFR mutation, treatment with adjuvant erlotinib or gefitinib 
was associated with a lower risk of recurrence or death, disease-free 
survival HR 0.43 (95% CI: 0.26–0.72, p = 0.001), and a trend toward 
improved OS. 
Conclusions: Patients with resected stage I–III lung cancers and 
EGFR mutation have a lower risk of death compared with patients 
without EGFR mutation. This may be because of treatment with 
EGFR TKIs. Patients with, and without KRAS mutation have similar 
OS. These data support reflex testing of resected lung adenocarcino-
mas for EGFR mutation to provide prognostic information and iden-
tify patients for enrollment on prospective clinical trials of adjuvant 
EGFR TKIs.
Key Words: EGFR, KRAS, Early-stage, Resected, Lung cancers, 
Non–small cell lung cancers, Adenocarcinomas.
(J Thorac Oncol. 2012;7: 1815–1822)
Complete surgical resection is the best way to cure patients with early-stage (I–III) non–small cell lung cancers 
(NSCLCs). Pathologic stage is the most important prognos-
tic factor for these patients, with 5-year survival proportions 
of 73% for pathologic stage IA, 58% for pIB, 46% for pIIA, 
36% for pIIB, 24% for pIIIA, and 9% for pIIIB.1 Patients with 
resectable stage II–III disease, who are treated with periopera-
tive cisplatin-based chemotherapy have a lower risk of death 
(approximate 20% relative risk reduction) compared with 
patients treated with surgery alone.2,3 Favorable prognostic 
factors include female sex, younger age, better performance 
status, lobectomy (as opposed to pneumonectomy or lesser 
resection), and squamous histology (for stages IB–II).4–7
Patients with stage IV NSCLCs and EGFR mutation 
have a better prognosis than patients without EGFR mutation, 
and are more likely to benefit from treatment with epidermal 
growth factor receptor (EGFR) tyrosine kinase inhibitors 
(TKIs).8–11 In patients with stage IV NSCLCs, KRAS mutations 
are not prognostic, and predict a lack of benefit from EGFR 
TKIs.12,13 In patients with surgically resected stage I–III lung 
cancers, data on the prognostic or predictive value of EGFR or 
KRAS mutations are limited.14–17
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Patients at Memorial Sloan-Kettering Cancer Center 
(MSKCC) with resected stage I–III lung adenocarcinomas 
have their tumor tested for EGFR and KRAS mutations as part 
of routine care, with results available to the medical oncolo-
gist during consideration of adjuvant therapy.18 The prognos-
tic value of EGFR and KRAS mutations in patients with lung 
adenocarcinomas has been assessed by our group in the past, 
with results published in the Journal of Thoracic Oncology in 
2008.19 This initial study included 296 total patients, of which 
14% and 17% of patients were found to have EGFR and KRAS 
mutations in their tumor tissue, respectively. Patients who had 
ever received treatment with an EGFR TKI (gefitinib or erlo-
tinib) were excluded from this initial study. After adjusting for 
stage, EGFR-mutant patients had a trend toward improved sur-
vival compared with those who were EGFR/KRAS wild-type, 
which did not reach statistical significance (HR 0.4, [95% CI: 
0.1–1.4]).19 Also in the Journal of Thoracic Oncology, our 
group has reported the impact of adjuvant EGFR TKI therapy 
on 167 patients with resected EGFR-mutant lung cancers in 
which date of disease recurrence was recorded to allow for 
analysis of disease-free survival.20 In this independent study, 
treatment with adjuvant erlotinib or gefitinib was associated 
with a trend toward improved disease-free and overall survival 
(OS) that did not reach statistical significance.20
This current study represents an update of both prior 
studies from our institution. The data sets for each study have 
been maintained and updated independently, but are reported 
here together, given their relevance.
MATERIALS AND METHODS
We analyzed tumor specimens from patients with surgi-
cally resected adenocarcinomas of the lung seen at MSKCC 
from January 2002 to December 2009, using an Institutional 
Review Board approved tissue procurement protocol. After 
microscopic examination confirmed the diagnosis of adeno-
carcinoma, tissue was sent to a molecular diagnostic labora-
tory in the Department of Pathology for extraction of DNA 
and identification of EGFR exon 19 deletions and exon 21 
L858R mutations by nonsequencing based polymerase chain 
reaction assays.21 In samples lacking these two sensitizing 
EGFR mutations, KRAS analysis was done by direct sequenc-
ing of exon 2 using polymerase chain reaction products.
Patients were excluded if they were found to have 
stage IV disease at the time of surgery or had incomplete 
resections. Compared with our prior study,19 this updated 
study included many more patients who had received treat-
ment with EGFR TKIs, both in the adjuvant setting, and at 
recurrence. A high risk of recurrence (i.e., higher stage), 
and actual recurrence, increased the likelihood of treatment 
with an EGFR TKI. As such, it was no longer reasonable 
to exclude patients who had received EGFR TKIs from the 
analysis. Therefore, in contrast to the prior study, all patients 
who received an EGFR TKI at any time in their treatment 
course were included in the analysis.
Pathologic stage was updated according to the American 
Joint Committee on Cancer guidelines, 7th edition.22 Smoking 
status was characterized as follows: never smokers (<100 life-
time cigarettes), former smokers (quit more than 1 year before 
diagnosis), or current smokers (quit less than 1 year before 
diagnosis). OS was determined using institutional databases 
and the Social Security Death Index. Clinical characteristics 
were compared among the three groups determined by mutation 
status (EGFR-mutant, KRAS-mutant, no mutation in EGFR or 
KRAS) using Fisher’s exact test. For OS, patients were followed 
from the date of surgery until death. Patients who were alive 
were censored at the time of the last available follow-up. OS 
was estimated using the Kaplan–Meier method, with follow-up 
starting at the time of surgical resection. Survival comparisons 
among groups were performed using the log-rank test adjusted 
for pathological stage.23 A multivariate Cox proportional haz-
ards model was fit to investigate the effect of mutation on OS, 
adjusted for age, sex, smoking status, and stratified by patho-
logical stage. The effect of perioperative platinum-based che-
motherapy was examined in all patients and separately for 
each pathological stage using Cox proportional hazard models 
adjusted for the same factors. Receipt of chemotherapy was 
treated as a time-dependent variable.
We also performed an update of our database made up 
exclusively of patients with completely resected stage I–III 
lung cancer and EGFR mutation identified by reflex testing.20 
This update included patients who had surgery through October 
2010 and therefore includes more patients identified to have 
EGFR mutation than the prior data set did, which included 
all resected patients from 2002 to 2009. This database also 
included detailed information regarding date of disease recur-
rence, allowing for analysis of both OS, and disease-free sur-
vival (DFS). For this update, follow-up was extended through 
July 2011. DFS was defined as time from surgical resection to 
cancer recurrence or death from any cause. DFS and OS were 
compared between patients with EGFR-mutant lung cancers 
who did, and did not receive an adjuvant EGFR TKI using 
multivariate Cox regression analyses.
In this data set, only dates of adjuvant erlotinib or gefi-
tinib delivery were recorded. Patients at MSKCC receive 
adjuvant erlotinib or gefitinib by enrolling in phase 2 clini-
cal trials,24,25 or outside of a clinical trial. In all cases, adju-
vant erlotinib or gefitinib is prescribed at the Food and Drug 
Administration approved dose for stage IV disease, with the 
goal to deliver daily oral therapy for up to 2 years. Whether 
on or off a research protocol, therapy is initiated after comple-
tion of all standard adjuvant chemotherapy (typically 4 cycles 
of cisplatin-based chemotherapy). Patients with resected 
IIIA(N2) disease also complete postoperative radiation ther-
apy before starting adjuvant EGFR TKI. In addition to up to 
2 years of postoperative therapy, a minority of patients also 
received gefitinib or erlotinib before surgery, for 21 days 
on protocol,24 or up to 3 months off protocol. Reasons for 
stopping postoperative erlotinib or gefitinib include disease 
recurrence, intolerable side effects, completion of 2 years of 
adjuvant therapy, or physician or patient preference. A minor-
ity of patients continued to take postoperative erlotinib or gefi-
tinib beyond 2 years based on physician or patient preference.
In the survival analysis, adjuvant erlotinib or gefitinib 
therapy was treated as a time-dependent factor, so that when it 
was given after the surgery, its effect would not be taken into 
account until the start of the EGFR TKI. All significance tests 
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were two-sided and used a 5% level of significance. Statistical 
analyses were performed using SAS (SAS Institute, Inc., 
Cary, NC) software and packages “clinfun” and “survcomp” 
in R (http://www.r-project.org/).
RESULTS
Demographics of 1118 patients with resected lung adeno-
carcinoma tested for EGFR and KRAS mutations are presented 
in Table 1. We detected KRAS mutations in 277 specimens 
(25%; 95% CI: 22%–27%) and EGFR mutations in 222 speci-
mens (20%; 95% CI: 18%–22%). More patients with EGFR-
mutant lung cancers were never smokers (60%) compared with 
KRAS (4%), p value was less than 0.001. Among individuals 
with EGFR-mutant lung cancers, 53 (24%) received adjuvant 
TKI, 19 (9%) received TKI only at recurrence, and 11 (5%) 
received it both in the adjuvant setting and at recurrence.
Patients had a median follow-up of 27 months (range, 
0.3–107 months). Median survival for all 1118 patients was 
77 months. Lower tumor stage and female sex were good 
prognostic factors (Table 2). Never smoking was also a sta-
tistically significant good prognostic factor.26 At 3 years, OS 
proportion among current smokers was 62% (95% CI: 53%–
73%), former smokers 77% (95% CI: 74%–81%), and never 
smokers 80% (95% CI: 75%–86%), p value was 0.03. There 
was no effect of age on the risk of death up to 65 years. After 
that, the risk of death increased linearly with age, with hazard 
ratio 1.05 (95% CI: 1.02–1.09, p = 0.005).
After adjusting for pathologic stage, the median OS 
was better for patients with EGFR-mutant lung cancers (83 
months, 95% CI: 76 months to not reached) compared with 
those with KRAS-mutant lung cancers (73 months, 95% CI: 
62 months to not reached), p value was 0.003. Three-year OS 
was 87% for individuals with EGFR-mutant tumors (95% 
CI: 81%–92%) and 75% with KRAS-mutant disease (95% 
CI: 69%–82%). In a multivariate analysis, the presence of an 
EGFR mutation predicted improved survival compared to a 
KRAS mutation, HR 0.48 (95% CI: 0.30–0.77, p = 0.002).
Patients with EGFR-mutant lung cancers had improved 
survival compared with patients who did not have EGFR-
mutant disease, adjusted HR 0.51 (95% CI: 0.34–0.76, p < 
0.001) (Fig. 1). In contrast, there was no difference in the sur-
vival of patients with tumors with and without a KRAS muta-
tion detected in their resection specimen, adjusted HR 1.17 
(95%CI: 0.87–1.57, p = 0.30) (Fig. 2).
A separate database includes only patients with resected 
lung adenocarcinoma and EGFR mutation identified at the 
time of surgery. Demographics of 286 patients with resected 
lung adenocarcinoma and EGFR mutation are presented in 
Table 3. Patients underwent surgery through July 2011, and 
median follow-up was 34 months (95% CI: 30–37, range, 
1–108 months). Eighty-four of 286 patients (29%) received 
adjuvant gefitinib or erlotinib. Median duration of adjuvant 
EGFR TKI was 18.6 months (range, 0.1–51.4 months).
Using a Cox regression analysis, patients with EGFR-
mutant lung cancers who received adjuvant gefitinib or erlo-
tinib demonstrated a longer disease-free survival than those 
who did not receive an adjuvant EGFR TKI, HR 0.43 (95%CI: 
0.26–0.72, p = 0.001) (Fig. 3). Patients who received adjuvant 
gefitinib or erlotinib showed a numerically superior OS, how-
ever, this difference was not significant, HR 0.50 (95% CI: 
0.23–1.08, p = 0.076) (Fig. 4). This observation of improved 
outcome in patients with resected NSCLCs and EGFR muta-
tion treated with adjuvant EGFR TKI is despite the fact that 
patients who received adjuvant EGFR TKI tended to have a 
TABLE 1.  Clinical Characteristics of 1118 Patients with Resected Stage I–III Lung 
Adenocarcinoma Tested for EGFR and KRAS Mutation
EGFR 
Mutation 
n = 222 
(20% of total)
KRAS  
Mutation  
n = 277 
(25% of total)
No EGFR or KRAS Mutation 
Detected 
n = 619 
(55% of total)
Median age, yrs (range) 68 (35–89) 68 (39–86) 68 (23–96)
Stage
 IA
 IB
 IIA
 IIB
 IIIA
 IIIB
120 (54%)
42 (19%)
15 (7%)
16 (7%)
27 (12%)
2 (1%)
150 (54%)
39 (14%)
25 (9%)
20 (7%)
37 (14%)
6 (2%)
318 (51%)
126 (20%)
46 (7%)
34 (6%)
72 (12%)
23 (4%)
Tumor size (cm) 
 <2 
 2–3 
 3–5 
 5–7 
 >7
106 (48%)
68 (31%)
45 (20%)
2 (<1%)
1 (<1%)
135 (49%)
69 (25%)
50 (18%)
10 (4%)
10 (4%)
299 (48%)
158 (26%)
116 (19%)
25 (4%)
10 (2%)
Cigarette smoking 
 Never 
 Former 
 Current
134 (60%)
84 (38%)
4 (2%)
12 (4%)
213 (77%)
52 (19%)
92 (15%)
435 (70%)
92 (15%)
Cytotoxic chemotherapy
 None 
 Adjuvant/neoadjuvant
176 (80%)
46 (21%)
214 (77%)
63 (23%)
440 (71%)
179 (29%)
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higher stage of disease (48% stage II–III), compared with 
patients who did not receive adjuvant EGFR TKI (16% stage 
II–III), p value was less than 0.001. Because patients who 
received adjuvant EGFR TKI tended to have a higher stage 
of disease, they were also more likely to have also received 
cytotoxic chemotherapy before starting adjuvant EGFR TKI 
(45% versus 16%, p < 0.001).
DISCUSSION
Despite successful surgery, half the patients with 
resected lung cancers suffer recurrence and death within 
5 years.27 Pathologic stage is the most important factor for 
selecting patients for adjuvant cisplatin-based chemotherapy, 
the only additional treatment known to improve the likelihood 
of cure. Other than stage, there are no validated clinical 
factors that predict the benefit of adjuvant treatment. Better 
prognostic and predictive biomarkers are needed to identify 
which patients should be treated with adjuvant therapy, and 
which agents to use.
In this analysis of 1118 patients with resected lung 
adenocarcinomas, we evaluated the prognostic significance 
of EGFR and KRAS mutations, conscious of the rising use 
of EGFR TKIs at recurrence and our institutional interest in 
studying adjuvant EGFR TKIs for patients with EGFR-mutant 
lung cancers.24,28 We limited EGFR mutation testing to the 
most common EGFR mutations, exon 19 deletions and exon 
21 L858R, which represent more than 90% of activating muta-
tions that impart erlotinib and gefitinib sensitivity. We limited 
KRAS mutation testing to the most common KRAS muta-
tions found in exon 2. Using these methods, and adjusting 
for potential confounders, we observed a lower risk of death 
in patients with EGFR-mutant lung cancers compared with 
all patients whose tumors did not harbor EGFR mutations, 
and compared with those with KRAS-mutant lung cancers. In 
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FIGURE 1.  OS comparing patients with EGFR-mutant versus 
EGFR wild-type tumors. OS, overall survival; CI, confidence 
interval; NA, not available.
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FIGURE 2.  OS comparing patients with KRAS-mutant versus 
KRAS wild-type tumors. OS, overall survival, CI, confidence 
interval; NA, not available.
TABLE 2.  Overall Survival Analysis for 1118 Patients with Resected Stage I–III Lung 
Adenocarcinoma Tested for EGFR and KRAS Mutation
Variable Category N 3-Yr Overall Survival (95% CI) p (Adjusted for Stage)
Stage
IA
IB
II
III
588
207
156
167
88% (84%–91%)
75% (68%-–82%)
62% (54%–72%)
53% (45%–62%)
Ref
0.002
<0.001
<0.001
Sex
F
M
710
408
80% (76%–84%)
70% (64%–75%)
Ref
0.001
Mutation type
EGFR mutation
KRAS mutation
222
277
87% (81%–92%)
75% (69%–82%)
Ref
0.003
Smoking history
Never
Former
Current
238
732
148
80% (75%–86%)
77% (74%–81%)
62% (53%–73%)
Ref
0.053
0.007
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contrast, detection of a KRAS mutation did not affect OS com-
pared with all patients without a KRAS-mutant tumor.
To our knowledge, this is the largest series evaluat-
ing the impact of EGFR mutations on survival in resected 
NSCLCs. The prognostic and predictive values of KRAS 
mutations have been studied in a series of 1500 patients with 
resected NSCLCs collected from trials in which patients were 
randomly assigned to surgery alone or surgery followed by 
adjuvant cisplatin-based chemotherapy (LACE-Bio).29 There 
were 303 patients (20%) in whom KRAS mutations were 
detected in their resection specimens. There was no difference 
in OS comparing patients with KRAS-mutant lung cancers 
with those with KRAS wild-type tumors (HR 1.18, p = 0.09).29 
No significant benefit of adjuvant chemotherapy was observed 
in patients with KRAS-mutant tumors (HR 1.02, 95% CI: 
0.73–1.41, p = 0.91), or in individuals with KRAS wild-type 
tumors (HR 0.89, 95% CI: 0.76–1.06, p = 0.20). There was no 
significant interaction to suggest that the presence of a KRAS 
mutation should be used as a predictive marker to select adju-
vant cisplatin-based chemotherapy. Our results confirm the 
lack of prognostic implications of KRAS mutation in resected 
lung cancer.
Recently, the prognostic roles of EGFR and KRAS muta-
tions were evaluated in 164 Taiwanese patients with resected 
disease.16 In that analysis, the median survival was numeri-
cally longer for patients with EGFR-mutant lung cancers (55 
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FIGURE 4.  OS in patients with EGFR-mutant lung cancer 
with (TKI) and without (no TKI) adjuvant gefitinib or erlo-
tinib. OS, overall survival, TKI, tyrosine kinase inhibitors; HR, 
hazard ratio.
FIGURE 3.  DFS in patients with EGFR-mutant lung cancer 
with (TKI) and without (no TKI) adjuvant gefitinib or erlo-
tinib. DFS, disease-free survival; TKI, tyrosine kinase inhibitors; 
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TABLE 3.  Clinical Characteristics of 286 Patients with Resected Stage I–III Lung Adenocarcinoma and 
EGFR Mutation Comparing Patients Who Did or Did Not Receive Treatment with Adjuvant EGFR TKI
Received Adjuvant EGFR TKI 
(n = 84)
No adjuvant EGFR TKI 
(n = 202)
p
Age, yrs: median (range) 65 (36–88) 70 (35–90) 0.002*
Sex—no. (%)
 Male 22 (26%) 54 (27%) 1.000
 Female 62 (74%) 148 (73%)
Pathologic stage—no. (%)
 I 44 (52%) 169 (84%) <0.001
 II 14 (17%) 17 (8%)
 III 26 (31%) 16 (8%)
Neoadjuvant/adjuvant cytotoxic chemotherapy—no. (%)
 Yes 38 (45%) 32 (16%) <0.001
 No 46 (55%) 170 (84%)
*p value calculated using Wilcoxon rank-sum test. Other p values calculated using Fisher’s exact test.
EGFR, ; TKI, tyrosine kinase inhibitor.
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months) than in individuals with EGFR and KRAS wild-type 
tumors (35 months). However, this difference was not signifi-
cant (p = 0.2). The 3-year survival for patients with EGFR-
mutant lung cancers was significantly better than the survival 
observed in those with tumors wild-type for EGFR and KRAS 
(p = 0.02). These differences did not change when the patients 
who received an EGFR TKI were removed from the analysis. 
In a larger study of Japanese patients, the superior survival of 
the patients with EGFR-mutant tumors compared with those 
with KRAS or TP53 gene mutations was no longer significant 
after multivariate analyses, although any patient who received 
an EGFR TKI was excluded from the survival analysis.15
The lower risk of death in patients with resected lung 
adenocarcinomas with EGFR mutations may be because of 
disease biology (EGFR mutation as a prognostic factor), or 
the effect of treatment with an EGFR TKI (EGFR mutation as 
a predictive factor). It is difficult to distinguish the prognostic 
from the predictive impact of an EGFR mutation in a retro-
spective study in which the patients who received an adjuvant 
EGFR TKI tended to have higher-stage disease, and patients 
who received any EGFR TKI tended to have recurrent disease. 
This bias toward treating patients with EGFR mutation and a 
higher risk of death with an adjuvant EGFR TKI in a retro-
spective study could underestimate the value of an EGFR TKI 
in reducing the risk of death.
In our study of patients with resected stage I-III NSCLC 
and EGFR mutation detected by reflex testing, we compared 
outcomes in patients who did, and did not receive treatment 
with adjuvant EGFR TKI. This study combined patients who 
had been treated with adjuvant EGFR TKI (either gefitinib 
or erlotinib) on two clinical trials at MSKCC, and also off 
protocol, for a total of 84 patients treated with adjuvant EGFR 
TKI. A prospective, placebo-controlled study (NCT00373425; 
RAndomized Double-blind trial In Adjuvant NSCLC with 
Tarceva, RADIANT) of adjuvant erlotinib in patients with 
resected NSCLC did not enrich exclusively for patients with 
EGFR mutation, and at close of enrollment was estimated to 
have included 113 patients with EGFR mutation, half of whom 
were randomized to placebo.29 Results of the RADIANT study 
are pending, with DFS as the primary endpoint. A prospective, 
placebo-controlled study (NCIC BR19) of adjuvant gefitinib 
in patients with resected NSCLC also did not enrich for EGFR 
mutation, and only genotyped 357 of 503 patients enrolled. Of 
those genotyped, only 76 patients were found to have EGFR 
mutations (40 in the placebo arm and 36 in the gefitinib arm).30
For all patients at MSKCC, in the RADIANT and NCIC 
BR19 studies, the goal has been to deliver up to 2 years of 
adjuvant EGFR TKI therapy. In our study, the median dura-
tion of adjuvant EGFR TKI therapy was 18.6 months. When 
adjusted for stage, age, sex, and smoking history, there was 
a reduced risk of disease recurrence in patients who had 
EGFR-mutant lung cancers and received adjuvant EGFR TKI 
compared with patients who had EGFR-mutant lung cancer 
and did not receive an adjuvant TKI; DFS HR 0.43 (95% 
CI: 0.26–0.72, p = 0.001). In contrast to our previous data 
published in the Journal of Thoracic Oncology in early 2011, 
this result shows the same trend but is now statistically sig-
nificant. The OS trend in this data set remains favorable, but 
is not statistically significant; HR 0.50 (95% CI: 0.23–1.08, 
p = 0.076).
Testing tumor tissue from patients with recurrent, or 
stage IV NSCLC for EGFR mutations is a standard of care.31,32 
Randomized phase III studies of patients with metastatic EGFR-
mutant lung cancers have demonstrated improved progression-
free survival and radiologic response rates with gefitinib or 
erlotinib compared with platinum-based chemotherapy.8–11 In 
addition, patients with stage IV EGFR-mutant lung cancers 
have a higher response rate to platinum-based chemotherapy 
compared with patients with EGFR wild-type tumors.10 Studies 
in patients with stage IV NSCLC also suggest that those with 
EGFR-mutant tumors have a better prognosis, with median sur-
vival times of 24 to 36 months compared with 12 months or 
less in those with EGFR wild-type tumors.33 No study in stage 
IV patients has ever shown an improvement in OS with earlier 
treatment with EGFR TKI because of crossover to EGFR TKI 
in patients initially treated with chemotherapy; however, sur-
vival trends are consistently favorable with the earlier use of 
EGFR TKI.8,9,11,33 On the basis of these results, it is no surprise 
that we observe improvements in DFS but not OS in our series 
of resected patients treated with adjuvant EGFR TKI.
At MSKCC, where patients with resected NSCLCs 
are prescribed adjuvant therapy with knowledge of EGFR 
mutation available, our team is cautious not to consider EGFR 
TKI as a substitute for standard adjuvant therapies. A question 
remains whether the presence of an EGFR mutation in 
patients with resected (stage I–III) NSCLCs could impact the 
effectiveness of standard adjuvant chemotherapy. A subgroup 
analysis from the National Cancer Institute of Canada JBR.10 
study looked for EGFR mutations in 436 of 482 patients with 
resected stage IB–II NSCLCs randomized to surgery alone, or 
surgery followed by adjuvant cisplatin + vinorelbine.34 EGFR 
mutations were identified in 43 patients (10%), of whom 27 
had been randomized to surgery alone, and 16 to surgery 
followed by cisplatin + vinorelbine. The benefit of adjuvant 
cisplatin + vinorelbine on DFS was numerically higher in the 
EGFR- mutant subgroup (HR 0.44, 95% CI: 0.11–1.70, p = 
0.22) than in the subgroup with EGFR wild-type tumors (HR 
0.78, 95% CI: 0.58–1.06, p = 0.12); however, this result was 
not significant (interaction p = 0.50).34
In our retrospective study, patients with EGFR muta-
tion who received adjuvant EGFR TKI tended to have a 
higher stage of disease, and were also more likely to have also 
received up to four cycles of cisplatin-based chemotherapy. 
This highlights physician preference to provide more adjuvant 
therapy for patients with a higher risk of recurrence and death. 
This bias may impact enrollment of high-risk patients into 
placebo-controlled studies of adjuvant EGFR TKI.
In summary, we report the largest cohort of patients with 
EGFR-mutant lung cancers with the longest follow-up after 
treatment with adjuvant erlotinib or gefitinib. Our data are pro-
vocative but have been generated by analyzing a large case 
series and not the results of a randomized clinical trial, and our 
conclusions constitute a lower level of evidence than would 
be provided by a randomized clinical trial. Our data carry the 
reassurance that adjuvant EGFR TKI will not increase the risk 
of death, and the side effects of these drugs are well known and 
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manageable. Also reassuring is our observation that patients 
treated with adjuvant EGFR TKI maintain sensitivity to EGFR 
TKI if they recur after stopping adjuvant therapy.34
We believe these data justify reflex testing of resection 
specimens from patients with NSCLCs for EGFR mutations 
because they predict a lower risk of death. These results also 
mandate a prospective, randomized trial of an adjuvant EGFR 
TKI in individuals with EGFR-mutant lung cancers to deter-
mine whether early treatment can prevent, or delay, recurrence 
and death. A 100-patient phase II study (NCT00567359)35 of 
adjuvant erlotinib for patients with resected EGFR-mutant 
lung cancers has completed enrollment, and early results 
are promising.36 An intergroup trial of adjuvant erlotinib for 
resected EGFR-mutant lung cancer sponsored by the National 
Cancer Institute, United States is planned.
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